A novel tumor-promoting function residing in the 5′ non-coding region of vascular endothelial growth factor mRNA

PLoS Medicine

Volumn 5, Issue 5, 2008, Pages 0805-0821

  Masuda, Kiyoshi ^a   Teshima Kondo, Shigetada ^a   Mukaijo, Mina ^a   Yamagishi, Naoko ^a   Nishikawa, Yoshiko ^a   Nishida, Kensei ^a   Kawai, Tomoko ^a   Rokutan, Kazuhito ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOHEXIMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN SYNTHESIS INHIBITOR; SIGNAL PEPTIDE; SMALL INTERFERING RNA; STAT1 PROTEIN; VASCULOTROPIN; VASCULOTROPIN 165; ANTINEOPLASTIC AGENT; STAT1 PROTEIN, HUMAN; VASCULOTROPIN A;

5' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HCT116; CELL SURVIVAL; CLONE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG INHIBITION; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44449097601     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050094     Document Type: Article

References (59)

1. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
2. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
3. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
4. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
5. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, et al. (1999) Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368.
6. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, et al. (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6: 373-378.
7. Hazelton D, Nicosia RF, Nicosia SV (1999) Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5: 823-829.
8. Minagawa N, Nakayama Y, Hirata K, Onitsuka K, Inoue Y, et al. (2002) Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res 22: 2957-2963.
9. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, et al. (2001) Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 8: 260-267.
10. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, et al. (2000) Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46: 938-947; discussion 947-948.
11. Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, et al. (2003) Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 18: 152-155.
12. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, et al. (2007) Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 8: 319-327.
13. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794.
14. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
15. Sandler AB, Johnson DH, Herbst RS (2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10: 4258s-4262s.
16. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, et al. (2007) Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4: e186. doi: 10.1371/journal.pmed.0040186
17. Costa FF (2005) Non-coding RNAs: new players in eukaryotic biology. Gene 357: 83-94.
18. Rastinejad F, Conboy MJ, Rando TA, Blau HM (1993) Tumor suppression by RNA from the 3′ untranslated region of alpha-tropomyosin. Cell 75: 1107-1117.
19. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER (2003) Tumor suppression by the prohibitin gene 39untranslated region RNA in human breast cancer. Cancer Res 63: 5251-5256.
20. Fan H, Villegas C, Huang A, Wright JA (1996) Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res 56: 4366-4369.
21. Blume SW, Miller DM, Guarcello V, Shrestha K, Meng Z, et al. (2003) Inhibition of tumorigenicity by the 5′-untranslated RNA of the human c-myc P0 transcript. Exp Cell Res 288: 131-142.
22. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, et al. (1998) Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 18: 6178-6190.
23. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, et al. (1998) Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17: 227-236.
24. Huez I, Bornes S, Bresson D, Creancier L, Prats H (2001) New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15: 2197-2210.
25. Teshima-Kondo S, Kondo K, Prado-Lourenco L, Gonzalez-Herrera IG, Rokutan K, et al. (2004) Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site. FASEB J: 03-1118fje.
26. Bornes S, Boulard M, Hieblot C, Zanibellato C, Iacovoni JS, et al. (2004) Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences. J Biol Chem 279: 18717-18726.
27. Martineau Y, Le Bec C, Monbrun L, Allo V, Chiu IM, et al. (2004) Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs. Mol Cell Biol 24: 7622-7635.
28. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucl Acids Res 31: 3406-3415.
29. Kawahara T, Kuwano Y, Teshima-Kondo S, Takeya R, Sumimoto H, et al. (2004) Role of nicotinamide adenine dinucleotide phosphate oxidase 1 in oxidative burst response to Toll-like receptor 5 signaling in large intestinal epithelial cells. J Immunol 172: 3051-3058.
30. Baird SD, Turcotte M, Korneluk RG, Holcik M (2006) Searching for IRES. RNA 12: 1755-1785.
31. Han B, Dong Z, Zhang JT (2003) Tight control of platelet-derived growth factor B/c-sis expression by interplay between the 5′-untranslated region sequence and the major upstream promoter. J Biol Chem 278: 46983-46993.
32. Prats AC, Prats H (2002) Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis. Prog Nucleic Acid Res Mol Biol 72: 367-413.
33. Battle TE, Frank DA (2002) The role of STATs in apoptosis. Curr Mol Med 2: 381-392.
34. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264.
35. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486.
36. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348.
37. Wang LH (2004) Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 71: 361-367.
38. Dhar D, Roy S, Das S (2007) Translational control of the interferon regulatory factor 2 mRNA by IRES element. Nucleic Acids Res 35: 5409-5421.
39. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, et al. (1998) Demonstration of an interferon gamma -dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556-7561.
40. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
41. Huang S, Bucana CD, Van Arsdall M, Fidler IJ (2002) Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21: 2504-2512.
42. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, et al. (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272: 28779-28785.
43. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, et al. (1998) Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 47: 113-120.
44. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, et al. (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95: 437-448.
45. Rosewicz S, Detjen K, Scholz A, von Marschall Z (2004) Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80 Suppl 1: 85-93.
46. Battle TE, Lynch RA, Frank DA (2006) Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 66: 3649-3657.
47. Sironi JJ, Ouchi T (2004) STAT1-induced apoptosis is mediated by Caspases 2, 3, and 7. J Biol Chem 279: 4066-4074.
48. Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, et al. (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22: 816-826.
49. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, et al. (1993) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735.
50. Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R (2002) Human interferon-gamma mRNA autoregulates its translation through a pseudo-knot that activates the interferon-inducible protein kinase PKR. Cell 108: 221-232.
51. Davis S, Watson JC (1996) In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3′ untranslated regions of human alpha -tropomyosin. Proc Natl Acad Sci U S A 93: 508-513.
52. Osman F, Jarrous N, Ben-Asouli Y, Kaempfer R (1999) A cis-acting element in the 3′-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR. Genes Dev 13: 3280-3293.
53. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, et al. (2006) Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70: 1032-1060.
54. Rastinejad F, Blau HM (1993) Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell 72: 903-917.
55. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680.
56. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599.
57. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
58. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799.
59. Los M, Roodhart JML, Voest EE (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450.